Mesalazine enteric-coated tablet and preparation method thereof

Through the inner and outer coating structure, pectin and copolymer materials are used to ensure that mesalazine enteric-coated tablets are not released early in the gastrointestinal tract and quickly released to the colon site, solving the problem of unreliable release of traditional drugs and realizing colon targets Reliability and stability of drug release to localization.

CN119015247APending Publication Date: 2024-11-26ANHUI TOPSUN PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411129269.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Mesalaxine enteric-coated tablets in traditional pH-dependent materials have poor pH differences between the small intestine and colon, resulting in unreliable drug release and difficult to achieve effective targeted delivery.

Method used

Adopt an inner and outer coating structure, where the inner coating consists of pectin, ethyl cellulose, plasticizer, pore-generating agent and enzyme trigger factor, and the outer coating consists of methacrylic acid and methyl methacrylate copolymer It is composed of plasticizers, and is formed by coating liquid spraying technology to ensure that the drug is not released early in the gastrointestinal tract and is quickly released when it reaches the colon.

Benefits of technology

It improves the reliability of colon-targeted localization and drug release of mesalazine enteric-coated tablets, ensures effective release of the drug at the colon site, and enhances the stability and release rate of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004997355010000071
    Figure BDA0004997355010000071
Patent Text Reader

Abstract

The invention discloses a mesalazine enteric-coated tablet and a preparation method thereof, and belongs to the technical field of chemical medicines. The mesalazine enteric-coated tablet comprises a plain tablet, an inner coating and an outer coating from inside to outside, and the preparation method comprises the following steps: mixing raw materials, sequentially carrying out wet granulation, drying, size stabilization and tabletting to obtain the plain tablet, and spraying on the surface of the plain tablet to form the inner coating and the outer coating, the outer coating is prepared by mixing a methacrylic acid and methyl methacrylate copolymer and a plasticizer, so that the tablet is not dissolved out under a simulated gastric acid condition, the outer coating is gradually dissolved in intestinal juice, pectin and ethyl cellulose in the inner coating are combined, and effective components in the tablet are protected from being basically not released in the simulated intestinal juice for 2 hours; and under the auxiliary action of the pore-foaming agent and the enzyme triggering factor, the mesalazine enteric-coated tablet in the colon liquid is simulated to release the drug quickly, so that the efficient colon-targeted positioning drug release of the mesalazine enteric-coated tablet is realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of chemical medicines, and particularly relates to a mesalazine enteric-coated tablet and a preparation method thereof. Background Art

[0002] Mesalazine is a 5-aminosalicylic acid preparation, which is clinically used for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). UC mainly invades the colon mucosa, usually starting from the left colon, and can develop to the proximal colon or even the entire colon. CD can occur in any part of the entire gastrointestinal tract, but it is more common in the terminal ileum and right colon. The molecular structure of mesalazine is relatively small. Oral tablets are quickly absorbed by the duodenum and upper jejunum, and it is difficult to reach the lesion sites such as the colon and terminal ileum. In order to ensure that the drug can effectively reach the lesion site to exert its effect, different drug dosage forms are made using different coatings. Common dosage forms include sustained-release tablets, enteric-coated tablets, sustained-release granules, enema solutions and suppositories. Among them, mesalazine enteric-coated tablets are suitable for maintenance treatment during the acute attack period of ulcerative colitis and to prevent recurrence, as well as to prevent acute attacks of Crohn's disease.

[0003] After being delivered to the colon, mesalazine enteric-coated tablets dissolve in the intestines, and the drug acts on the inflamed mucosa, which has a significant anti-inflammatory effect. The outer layer of mesalazine enteric-coated tablets is coated with a film, the purpose of which is to deliver the drug to the colon in a targeted manner, control the diffusion and dissolution of the drug, and delay the release of the drug. Its delivery process is called an oral colon-targeted drug release system, which refers to a drug release system that uses appropriate methods to prevent the drug from being released in the stomach, duodenum, jejunum, and the front end of the ileum, and directly delivers it to the ileum and cecum of the patient, where most or all of the drug is released to exert a therapeutic effect. It has the characteristics of specific response to the local environment of the colon.

[0004] The release of mesalazine enteric-coated tablets is affected by many factors, such as the pathological characteristics of the colon disease site, the biological and physicochemical properties of the active ingredients, the pH of the gastrointestinal tract, the time it takes for the drug to reach the colon, diet and colon flora, etc., which brings challenges to the research and design of targeted delivery. The main drug delivery method at present is pH-dependent, which uses the pH difference of the gastrointestinal tract to wrap the drug with pH-dependent materials, so that the drug is not released in the stomach and small intestine with a lower pH, but is released in the colon with a higher pH, thereby achieving targeted release of the drug. However, due to pathological factors, the pH difference between the small intestine and the colon is not obvious, resulting in the possibility that the material that only depends on the pH of the colon may be released early or late, and the targeting performance is unreliable. Summary of the invention

[0005] The purpose of the present invention is to provide a mesalazine enteric-coated tablet and a preparation method thereof, so as to improve the reliability of colon-targeted drug release of mesalazine.

[0006] The purpose of the present invention can be achieved by the following technical solutions:

[0007] The present invention provides a mesalazine enteric-coated tablet, which comprises a plain tablet, an inner coating and an outer coating from the inside to the outside;

[0008] The raw materials of the inner coating include pectin, ethyl cellulose, plasticizer, pore former and enzyme triggering factor;

[0009] The raw materials of the outer coating include methacrylic acid and methyl methacrylate copolymer and plasticizer.

[0010] Furthermore, the raw materials of the plain tablets include:

[0011] By weight, mesalazine 105 parts, pregelatinized starch 0.2-0.6 parts, low-substituted hydroxypropyl cellulose 8-12 parts, binder 0.1-0.4 parts, micro powder silica gel 1-1.5 parts, disintegrant 2-5 parts, lubricant 1-1.5 parts

[0012] Furthermore, the binder is corn starch; the disintegrant is sodium starch glycolate; and the lubricant is magnesium stearate.

[0013] Adding an appropriate amount of disintegrant to the drug can make it have higher disintegration performance, and adding a lubricant can make the drug ingredients more easily absorbed by water, thereby promoting the release and absorption of the drug.

[0014] Furthermore, in the raw materials of the inner coating, the plasticizer is triethyl citrate, the pore-forming agent is sorbic acid, and the enzyme trigger factor is the starch derivative Nutriose.

[0015] Furthermore, the coating solution of the inner coating is prepared as follows:

[0016] According to weight proportions, 5-9 parts of pectin, 8-12 parts of ethyl cellulose, 0.5-3 parts of starch derivative Nutriose, 2-3 parts of triethyl citrate and 1-4 parts of sorbic acid are dissolved in an ethanol aqueous solution to form a coating solution for an inner layer coating with a solid content of 25%, wherein the mass fraction of ethanol in the ethanol aqueous solution is 80%.

[0017] Furthermore, in the raw materials of the outer coating, the methacrylic acid and methyl methacrylate copolymer is a mixture of Eudragit S100 and Eudragit L100, and the plasticizer is triethyl citrate.

[0018] Furthermore, the coating solution of the outer coating is prepared as follows:

[0019] Eudragit S100 and Eudragit L100 are dissolved in a mixed solvent of ethanol and water at a mass ratio of 1:1, and triethyl citrate is added and mixed evenly to form a coating solution for an outer coating with a solid content of 30%. The mass fraction of triethyl citrate in the coating solution for the outer coating is 3%, and the volume ratio of ethanol to water in the mixed solvent is 8:2.

[0020] Eudragit L100 is a copolymer of methacrylic acid and methyl methacrylate (1:1), and Eudragit S100 is a copolymer of methacrylic acid and methyl methacrylate (1:2).

[0021] Eudragit S100 dissolves at pH>7.0, and Eudragit L100 dissolves at pH>6.0. Mixing the two in different proportions can control dissolution under different pH conditions.

[0022] Furthermore, the mass ratio of the inner coating to the plain tablet is 0.02-0.03:1;

[0023] The mass ratio of the outer coating to the plain tablet is 0.05-0.06:1.

[0024] Furthermore, the mass of the plain mesalazine enteric-coated tablets is 0.48 g.

[0025] The present invention also provides a method for preparing mesalazine enteric-coated tablets, comprising the following steps:

[0026] S1. Mix the raw materials of the plain tablets evenly according to the ratio, put them into a wet mixing granulator to form granules, and dry them in a boiling drying granulator;

[0027] S2, putting the dried granules into a lifting and turning granulating machine for granulating;

[0028] S3, adding lubricant and disintegrant to the granules after granulation, mixing evenly, putting into high-speed tablet press, punching and tableting to obtain plain tablets;

[0029] S4. Spray the coating liquid of the inner coating onto the surface of the plain tablet by a coating machine to form an inner coating, and then spray the coating liquid of the outer coating onto the surface to form an outer coating, and obtain mesalazine enteric-coated tablets after drying.

[0030] Beneficial effects of the present invention:

[0031] The coating material of the mesalazine enteric-coated tablets prepared by the invention comprises an inner coating and an outer coating, and the effective components of the mesalazine enteric-coated tablets are not released to the outside when passing through the stomach and small intestine. The outer coating can prevent gastric acid decomposition. When entering the small intestine, the outer coating slowly dissolves under the high pH environment of the intestine. The inner coating based on pectin and water-insoluble ethyl cellulose can protect the effective components from being released in the small intestine. When in the colon, the starch derivative Nutriose acts as an enzyme triggering factor to promote the generation of pectin decomposing enzymes. At the same time, the pore-forming agent sorbic acid can accelerate the release rate, so that the drug can be well dissolved and released, so as to realize the colon-targeted release of mesalazine and improve the stability of the drug. DETAILED DESCRIPTION

[0032] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0033] Example 1

[0034] Preparation of coating solution for inner coating:

[0035] According to weight proportions, 5 parts of pectin, 12 parts of ethyl cellulose, 0.5 parts of starch derivative Nutriose, 3 parts of triethyl citrate and 4 parts of sorbic acid are dissolved in an ethanol aqueous solution to form a coating solution for an inner layer coating having a solid content of 25%, wherein the mass fraction of ethanol in the ethanol aqueous solution is 80%.

[0036] Prepare the coating solution for the outer coating:

[0037] Eudragit S100 and Eudragit L100 were dissolved in a mixed solvent of ethanol and water in a volume ratio of 8:2 at a mass ratio of 1:1, and triethyl citrate was added and mixed evenly to form a coating solution with a solid content of 30% for the outer coating, and the mass fraction of triethyl citrate in the coating solution for the outer coating was 3%.

[0038] Preparation of Mesalazine Enteric-coated Tablets:

[0039] Prepare the raw materials for the plain tablets according to the weight proportions: 105 parts of mesalazine, 0.2 parts of pregelatinized starch, 12 parts of low-substituted hydroxypropyl cellulose, 0.4 parts of corn starch, 1 part of micro powder silica gel, 2 parts of sodium carboxymethyl starch and 1.5 parts of magnesium stearate.

[0040] S1. Mix mesalazine, pregelatinized starch, low-substituted hydroxypropyl cellulose and micro-powdered silica gel evenly, add corn starch, put into a wet mixing granulator to form granules, and dry in a boiling drying granulator;

[0041] S2, putting the dried granules into a lifting and turning granulating machine for granulating;

[0042] S3, adding magnesium stearate and sodium carboxymethyl starch to the granules after granulation, mixing evenly, putting into a high-speed tablet press, punching and pressing to obtain plain tablets;

[0043] S4. Spray the coating liquid of the inner coating onto the surface of the plain tablet by a coating machine to form an inner coating, and then spray the coating liquid of the outer coating onto the surface to form an outer coating, and obtain mesalazine enteric-coated tablets after drying.

[0044] The mass ratio of the inner coating layer and the plain tablet of the prepared mesalazine enteric-coated tablets was 0.025:1, the mass ratio of the outer coating layer and the plain tablet was 0.055:1, and the mass of the plain tablet in the mesalazine enteric-coated tablets was 0.48 g.

[0045] Example 2

[0046] The other steps are the same as those in Example 1, except that the raw material ratio of the coating solution for the inner coating is different, and the specific ratio is 8 parts of pectin, 10 parts of ethyl cellulose, 2 parts of starch derivative Nutriose, 2.5 parts of triethyl citrate and 2 parts of sorbic acid.

[0047] Example 3

[0048] The other steps are the same as those in Example 1, except that the raw material ratio of the coating solution for the inner coating is different, and the specific ratio by weight is: 9 parts of pectin, 8 parts of ethyl cellulose, 3 parts of starch derivative Nutriose, 2 parts of triethyl citrate and 1 part of sorbic acid.

[0049] Example 4

[0050] The other steps were the same as those in Example 1, except that the mass ratio of the inner coating layer of the prepared mesalazine enteric-coated tablets to the plain tablets was 0.02:1.

[0051] Example 5

[0052] The other steps were the same as those in Example 1, except that the mass ratio of the inner coating layer of the prepared mesalazine enteric-coated tablets to the plain tablets was 0.03:1.

[0053] Example 6

[0054] The other steps were the same as those in Example 1, except that the mass ratio of the outer coating of the prepared mesalazine enteric-coated tablets to the plain tablets was 0.05:1.

[0055] Example 7

[0056] The other steps were the same as those in Example 1, except that the mass ratio of the outer coating of the prepared mesalazine enteric-coated tablets to the plain tablets was 0.06:1.

[0057] Example 8

[0058] The other steps are the same as those in Example 1, except that the raw material ratios for preparing the mesalazine enteric-coated tablets are different. The specific ratios are as follows by weight: 105 parts of mesalazine, 0.4 parts of pregelatinized starch, 10 parts of low-substituted hydroxypropyl cellulose, 0.2 parts of corn starch, 1.2 parts of micropowdered silica gel, 4 parts of sodium carboxymethyl starch, and 1.3 parts of magnesium stearate.

[0059] Example 9

[0060] The other steps are the same as those in Example 1, except that the raw material ratios for preparing the mesalazine enteric-coated tablets are different. The specific ratios are as follows by weight: 105 parts of mesalazine, 0.6 parts of pregelatinized starch, 8 parts of low-substituted hydroxypropyl cellulose, 0.1 parts of corn starch, 1.5 parts of micro powder silica gel, 5 parts of sodium carboxymethyl starch, and 1 part of magnesium stearate.

[0061] Comparative Example 1

[0062] Mesalazine enteric-coated tablets were prepared according to the preparation method provided in Example 3 of Patent No. CN102784154B.

[0063] Comparative Example 2

[0064] Mesalazine enteric-coated tablets were prepared according to the preparation method provided in Example 3 of Patent No. CN112315929B.

[0065] Take 10 tablets of each of the mesalazine enteric-coated tablets prepared in Examples 1-9 and Comparative Examples 1 and 2, and place them in a container filled with simulated gastric juice (1 g of pepsin dissolved in 100 mL of HCl solution, pH 1.0) for 2 h, take them out and wash them with water, and then place them in a container filled with simulated small intestinal juice (1 g of pancreatic enzyme powder dissolved in 100 mL of phosphate buffer solution, pH 6.8) for 2 h, and finally take them out and wash them with water, and place them in a container filled with simulated colon juice (the colon of SD rats was paralyzed and taken out from the abdomen, and 30 g of colon contents were collected in a nitrogen-filled environment and dissolved in 100 mL of phosphate buffer solution, pH 7.8) for 15 min, and the release of the enteric-coated tablets at different stages was detected, and the results are shown in Table 1.

[0066] Table 1

[0067]

[0068] (1) From the results of Examples 1 to 3 in Table 1, it can be seen that the proportion of pectin and ethyl cellulose in the inner coating of mesalazine enteric-coated tablets affects its release rate in colonic fluid. An increase in the proportion of pectin and the starch derivative Nutriose is conducive to the degradation of the inner coating by enzymes in the simulated colonic fluid, promotes the dissolution of the inner coating, and increases the release rate of the active ingredient. However, when the proportion is too high, due to the limited amount of decomposition enzymes produced in the simulated colonic fluid in a short period of time, its promoting effect on the release rate shows a downward trend.

[0069] (2) From the results of Example 4 and Example 5 in Table 1, combined with Example 1, it can be seen that the mass ratio of the inner coating to the plain tablet has a great influence on the release rate of mesalazine enteric-coated tablets in simulated colonic fluid. The larger the mass ratio of the inner coating to the plain tablet, the slower the release rate in simulated colonic fluid. When the mass ratio reaches 0.03:1, the release rate in simulated colonic fluid for 15 minutes is less than 90%. On the contrary, the larger the mass ratio, the smaller the release rate in simulated small intestinal fluid. This is because the thicker the inner coating, the better the protection effect of the effective components in simulated small intestinal fluid with a pH of 6.8.

[0070] (3) From the results of Example 6 and Example 7 in Table 1, combined with Example 1, it can be seen that the mass ratio of the outer coating and the plain tablet affects the release of mesalazine enteric-coated tablets in simulated small intestinal fluid. The larger the ratio, the longer the dissolution time of the outer coating, and the lower the release of its active ingredient.

[0071] (4) From the results of Example 8 and Example 9 in Table 1, combined with Example 1, it can be seen that as the proportion of disintegrant in the raw material of the plain tablet increases, the release rate of mesalazine enteric-coated tablets in the simulated colonic fluid will increase accordingly.

[0072] (5) Combining the results of Comparative Examples 1-2 and Example 1 in Table 1, it can be seen that the mesalazine enteric-coated tablets prepared by the present invention can avoid the premature release of the active ingredient and can quickly release the drug in the colon, and have a reliable colon-targeted drug release effect.

[0073] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device.

[0074] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A mesalazine enteric-coated tablet, It is characterized in that The mesalazine enteric-coated tablets include a plain tablet, an inner coating and an outer coating from the inside to the outside; The raw materials of the inner coating include pectin, ethyl cellulose, plasticizer, pore former and enzyme triggering factor; The outer coating includes methacrylic acid and methyl methacrylate copolymer and a plasticizer.

2. A mesalazine enteric-coated tablet according to claim 1, It is characterized in that The raw materials of the plain tablets include: By weight, the composition comprises 105 parts of mesalazine, 0.2-0.6 parts of pregelatinized starch, 8-12 parts of low-substituted hydroxypropyl cellulose, 0.1-0.4 parts of binder, 1-1.5 parts of micro powder silica gel, 2-5 parts of disintegrant and 1-1.5 parts of lubricant.

3. A mesalazine enteric-coated tablet according to claim 2, It is characterized in that The binder is corn starch; the disintegrant is sodium starch glycolate; and the lubricant is magnesium stearate.

4. A mesalazine enteric-coated tablet according to claim 1, It is characterized in that The plasticizer in the raw materials of the inner coating is triethyl citrate, the pore-forming agent is sorbic acid, and the enzyme trigger factor is the starch derivative Nutriose.

5. A mesalazine enteric-coated tablet according to claim 4, It is characterized in that The coating solution of the inner coating is prepared as follows: According to weight proportions, 5-9 parts of pectin, 8-12 parts of ethyl cellulose, 0.5-3 parts of starch derivative Nutriose, 2-3 parts of triethyl citrate and 1-4 parts of sorbic acid are dissolved in an ethanol aqueous solution to form a coating solution for an inner layer coating with a solid content of 25%, wherein the mass fraction of ethanol in the ethanol aqueous solution is 80%.

6. A mesalazine enteric-coated tablet according to claim 1, It is characterized in that The raw materials of the outer coating layer include a copolymer of methacrylic acid and methyl methacrylate, which is a mixture of Eudragit S100 and Eudragit L100, and a plasticizer, which is triethyl citrate.

7. A mesalazine enteric-coated tablet according to claim 6, It is characterized in that The coating solution of the outer coating is prepared as follows: Eudragit S100 and Eudragit L100 are dissolved in a mixed solvent of ethanol and water at a mass ratio of 1:1, and triethyl citrate is added and mixed evenly to form a coating solution for an outer coating with a solid content of 30%. The mass fraction of triethyl citrate in the coating solution for the outer coating is 3%, and the volume ratio of ethanol to water in the mixed solvent is 8:

2.

8. A mesalazine enteric-coated tablet according to claim 1, It is characterized in that The mass ratio of the inner coating to the plain tablet is 0.02-0.03:1; The mass ratio of the outer coating to the plain tablet is 0.05-0.06:

1.

9. A mesalazine enteric-coated tablet according to claim 1, It is characterized in that The mass of the plain mesalazine enteric-coated tablets is 0.48 g.

10. A method for preparing the mesalazine enteric-coated tablets according to any one of claims 1 to 9, It is characterized in that The following steps are involved: S1. Mix the raw materials of the plain tablets evenly according to the ratio, put them into a wet mixing granulator to form granules, and dry them in a boiling drying granulator; S2, putting the dried granules into a lifting and turning granulating machine for granulating; S3, adding lubricant and disintegrant to the granules after granulation, mixing evenly, putting into high-speed tablet press, punching and pressing to obtain plain tablets; S4. Spray the coating liquid of the inner coating onto the surface of the plain tablet by a coating machine to form an inner coating, and then spray the coating liquid of the outer coating onto the surface to form an outer coating, and obtain mesalazine enteric-coated tablets after drying.